Answers are grounded in this paper and cite their sources.
Introduction Selinexor, an XPO1 inhibitor, has emerged as a promising therapeutic option in the challenging landscape of relapsed/refractory multiple myeloma (RRMM).
No takes yet. Share an insight, caveat, or question.
Martino et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: